Little is known about the long-term side-effects of different treatments for hyperthyroidism. The few studies previously published on the subject either included only women or focused mainly on cancer outcomes. This register study compared the impact of surgery versus radioiodine on all-cause and cause-specific mortality in a cohort of men and women.
Introduction
The lifetime prevalence of hyperthyroidism in iodine-replete communities is about 2 per cent in women and 0⋅2 per cent in men 1, 2 . The most common cause of hyperthyroidism is Graves' disease followed by toxic nodular goitre. For both of these diagnoses, there are three main therapeutic alternatives that have all been available for over half a century: radioactive iodine (henceforth referred to as radioiodine), surgery (thyroidectomy) and antithyroid drugs. The purpose of radioiodine ablation or surgery is to reduce permanently the amount of active thyroid gland tissue in order to achieve hypothyroidism. By contrast, the effect of antithyroid drugs is reversible.
Several criteria exist to guide the choice of treatment for each individual 3 . For instance, radioiodine is rarely recommended for young women or patients with large goitres, whereas surgery is seldom performed in frail and/or elderly patients. In patients with Graves' disease, eye symptoms due to thyroid-associated ophthalmopathy may develop or worsen if radioiodine is given uncritically, although this side-effect may, in most patients, be avoided if steroid prophylaxis is used 3 -5 . Surgery, on the other hand, may result in damage to the recurrent laryngeal nerve or cause hypoparathyroidism. Antithyroid drugs are associated with a slight risk of cutaneous side-effects, agranulocytosis or hepatic injury, and carry a high risk of relapse into hyperthyroidism once treatment is discontinued. Clinical criteria notwithstanding, the subjective preference of the individual patient plays an important role in the choice of 1 Generation of the study cohort and sources of data treatment, as do logistical and sometimes economic issues. In addition, regional differences exist, as radioiodine is used more frequently in the USA than in Europe and Japan, whereas the opposite is true for surgery 6, 7 .
Much research, including several RCTs 4, 5, 8 , have been performed to compare efficacy and short-term complications between treatments, mostly in terms of relapse into hyperthyroidism and/or progression of ophthalmopathy. A recent meta-analysis 9 concluded that, in patients with Graves' disease, radioiodine and surgery were equally effective in terms of relapse prevention, but antithyroid drugs were less effective. Only a few studies have, however, investigated other adverse long-term effects. Of these, two 10, 11 are relatively old and included only women, whereas two other studies 12,13 focused on cancer incidence and cancer mortality. Another study 14 did involve long-term follow-up of patients who had been randomized to different treatments, but the number of individuals was small and outcomes were assessed only in terms of quality of life.
The aim of the present study was thus to compare cause-specific mortality between hyperthyroid patients, both men and women, treated with either radioiodine or surgery after long-term follow-up.
Methods
The study was approved by the Ethical Review Board of Stockholm (reference number 2013/638-31/3).
Assembly of the study cohort is described in Fig. 1 . As in all Nordic countries, Sweden has a system of personal identity numbers that has been in use since the 1950s. These are unique identifiers given to each individual at birth or immigration; they are used in virtually all contacts with authorities and healthcare establishments, thus enabling cross-matching between all Swedish registers that contain personal data of any kind.
In this study, patients treated with radioiodine for hyperthyroidism were identified using the Stockholm Radioiodine Cohort, a database compiled from the hospital records of Radiumhemmet at Karolinska University Hospital, which has always been the sole provider of this therapy in the greater Stockholm area. It contains detailed information on investigations and treatments where radioactive isotopes have been used; for hyperthyroid patients, the probable aetiology of hyperthyroidism is stated in over 90 per cent of cases, as well as details about the treatment (doses of radioiodine, number of treatments, etc.). Although the database is part of a nationwide equivalent that covers the years 1950-2000, it is considered to be essentially complete for the greater Stockholm area only during the years 1976-2000. The cohort has been described and used for research previously 15 -17 . Stockholm residents treated with surgery for hyperthyroidism were assembled from the Swedish National Patient Register, which contains diagnosis and procedure codes for virtually all inpatient hospital contacts including thyroidectomies (but not radioiodine treatment, which is considered to be outpatient care) in Sweden from 1964 to the present. The Patient Register is managed by the Swedish National Board of Health and Welfare, and has been validated and used for research previously 18 . The study cohort was compiled by merging extracted data on Stockholm residents for the years 1976-2000, using each individual's personal identity number. All individuals (both radioiodine treated and surgically treated) were then matched to the entire Patient Register for the period 1969-2000 to find other diagnoses, related to any earlier hospitalizations, that would constitute relevant baseline co-morbidity. A similar procedure has been performed recently by this research group in another study 19 . The following exclusion criteria were applied: individuals aged 35 years or younger, as this age category is seldom eligible for radioiodine treatment; patients with uncertain aetiology of hyperthyroidism; and individuals who had been treated with both radioiodine and surgery.
The primary outcome was all-cause mortality; secondary outcomes were death from cardiovascular disease, cancer or other cause. These were assessed by gathering information on vital status from Statistics Sweden, a national agency responsible for census data, and the Swedish Causes of Death Register, which is managed by the National Board of Health and Welfare 20 . This was done for the period 1976-2012, with the exception of all-cause mortality, which was assessed to the end of 2013. The Causes of Death Register is based on data from death certificates, in which a physician must state an underlying cause of death, but where contributing causes may also be added when this is deemed relevant. As contributing causes are not always stated, a choice was made to analyse only underlying causes in this study. For an overview of diagnostic code definitions, see Table S1 (supporting information).
Statistical analysis
Frequencies (percentages) were used to present the baseline characteristics of the study cohort according to surgery or radioiodine treatment, and compared using the χ 2 test. Standardized differences were used to assess the balance of the baseline characteristics in the two treatment groups 21 . In general, absolute values of the standardized difference below 0⋅1 are desirable, as absolute values greater than 0⋅1 may indicate meaningful imbalance in the co-variables 21, 22 .
To assess the association between treatment and the study outcomes, while trying to remove the imbalance in the potential confounders between the treatment groups, three different statistical methods were employed: regression adjustment, propensity score matching, and inverse probability weighting 23 . For regression analyses, a Cox regression model was used that adjusted for all the potential confounders presented in Table 1 to estimate hazard ratios (HRs) and 95 per cent confidence intervals. For propensity score matching and inverse probability weighting analyses, propensity scores estimating the probability of receiving surgical treatment were calculated using a logistic regression model. The propensity score model included as co-variables the potential confounders listed in Table 1 . For propensity score matching analysis, a one-to-one nearest-neighbour matching algorithm without replacement was employed, to pair each patient receiving surgical treatment with one receiving radioiodine treatment. A caliper equal to 0⋅2 times the standard deviation of the log-odds of the propensity score was used 24 . All patients who had surgery were matched successfully to one radioiodine patient. Propensity score matching allows estimation of the average treatment effect among those treated. This measure allows one to make inference about the effect of surgical treatment in the population of patients who actually underwent surgery. For inverse probability weighting analyses, standardized mortality ratio weights were employed 25 . Briefly, this means that surgical patients are given a weight of 1, whereas patients treated by radioiodine are given a weight equal to the ratio of the estimated propensity score to 1 minus the propensity score. A choice was made to use standardized mortality ratio weights as their use results in an estimate of the average treatment effect among the treated, which is the same quantity estimated in the aforementioned propensity score analysis. After matching or weighting, a check was again made for balance in the confounders using standardized differences. Finally, for both propensity score matching and inverse probability weighting analyses, Cox regression models including treatment as the only co-variable were used. To account for the matched nature of the sample (propensity score matching) or for the probability weights, a robust estimator of the variance-covariance matrix was employed 23 .
Because very few patients older than 75 years were treated with surgery, a sensitivity analysis was performed using only subjects aged 35-75 years.
All analyses were performed in Stata ® 14.2 software (StataCorp, College Station, Texas, USA).
Results
Between January 1976 and March 2000, 10 992 Stockholm residents aged over 35 years with either Graves' disease or toxic nodular goitre received one of the two analysed treatments. Of these, 10 250 had been treated with radioiodine and 742 with surgery ( Fig. 1) . The median age was 
Values in parentheses are percentages. SD, standardized difference; COPD, chronic obstructive pulmonary disease; TAO, thyroid-associated ophthalmopathy. *χ 2 test. Values in parentheses are 95 per cent confidence intervals. Mean duration of follow-up was 16⋅3 years when regression analysis was applied, and 22⋅3 years for propensity score matching and inverse probability weighting. *The number of all-cause deaths exceeds the sum of deaths from specific causes as no data on causes of death were available for 2013. †P = 0⋅044 for this observation.
65⋅1 years for the radioiodine group and 44⋅1 years for the surgery group. Sex ratios were comparable, with women comprising 84⋅6 and 85⋅3 per cent respectively in each group. As might be expected given the large age difference between groups, levels of baseline co-morbidity were substantially higher among radioiodine-treated patients ( Table 1) .
Analysis of mortality
In the regression analyses, 7007 individuals died during follow-up. The number of person-years at risk was 179 409, with a mean duration of follow-up of 16⋅3 years. The HR for all-cause death was 0⋅82 (95 per cent c.i. 0⋅71 to 0⋅96) for surgically treated compared with radioiodine-treated patients. The risk of death from cardiovascular causes 2 Overall survival of patients treated for hyperthyroidism with surgery versus radioiodine in the propensity score matching analysis was likewise reduced (HR 0⋅70, 0⋅53 to 0⋅91), whereas no statistically significant difference was found for cancer mortality (HR 1⋅04, 0⋅80 to 1⋅36) or death from other causes (HR 0⋅78, 0⋅59 to 1⋅04) for surgery versus radioiodine ( Table 2) . Separate analyses according to sex yielded a significant risk difference among men (HR 0⋅46, 0⋅31 to 0⋅68) but not among women (HR 0⋅94, 0⋅80 to 1⋅10; P < 0⋅001 for interaction).
In the propensity score matching analyses, 1484 individuals were matched, 400 of whom died during follow-up (Fig. 2) . Total observation time was 33 074 person-years, yielding a mean duration of follow-up of 22⋅3 years. Co-variables were well balanced, with all absolute standardized differences lower than 0⋅1 ( Table 3 ). For the surgery group, the HR for all-cause death was 0⋅80 (95 per cent c.i. 0⋅68 to 0⋅94) and that for cardiovascular death was 0⋅64 (0⋅48 to 0⋅86) compared with the radioiodine group. No significant differences were found for death from cancer or other causes ( Table 2) . 
Values in parentheses are percentages. SD, standardized difference; COPD, chronic obstructive pulmonary disease; TAO, thyroid associated ophthalmopathy. *Synthetic n values derived from weights and rounded to the nearest integer; the sum of subgroups may differ from the total sum owing to rounding errors. 3 Overall survival of patients treated for hyperthyroidism with surgery versus radioiodine in the inverse probability weighting analysis Inverse probability weighting analyses included 1478 individuals. Of these, 387 died during a mean follow-up of 22⋅3 years, or 32 911 person-years at risk in total (Fig. 3) . Again, all absolute standardized differences were lower than 0⋅1 ( Table 3) . The difference in risk for all-cause death was 0⋅85 (95 per cent c.i. 0⋅72 to 1⋅00; P = 0⋅044) and that for cardiovascular mortality was 0⋅74 (0⋅56 to 0⋅97) for surgery versus radioiodine. No significant differences were seen regarding cancer mortality or deaths from other causes ( Table 2) .
In the sensitivity analysis, 2413 patients older than 75 years were excluded (a total of 13 thyroidectomies and 2400 radioiodine treatments). This did not lead to any statistically significant changes in the regression or inverse probability weighting analyses. In the propensity score matching, no difference in all-cause death remained, whereas increased cancer mortality was found in the surgery group (HR 1⋅65, 95 per cent c.i. 1⋅11 to 2⋅46).
Discussion
The main conclusion of this study is that, compared with surgery, radioiodine treatment for hyperthyroidism was associated with an increased risk of death during long-term follow-up. The difference in cardiovascular mortality between groups was the main reason for this finding. Men, in particular, appeared to be at great risk when treated with radioiodine. In general, the results did not vary significantly across the different statistical methods used.
A few previous studies have examined retrospectively the long-term effects of different treatments for hyperthyroidism. The first was performed at the Mayo Clinic in 1982, where Hoffman and colleagues 10 studied 3146 women treated with radioiodine or surgery and found no difference in mortality between the groups. In 1988, Goldman and co-workers 11 found a slightly increased risk of cardiovascular death in 1932 US residents treated with radioiodine compared with surgery or antithyroid drugs; again, only women were included. More recently, two studies, one from the USA 12 and one from Finland 13 , examined cancer incidence and cancer mortality in both men and women with regard to treatment modality; no significant differences were found. In 2013, Boelaert et al. 26 compared all-cause mortality in British patients treated with either radioiodine or antithyroid drugs and found no clear differences.
The present finding of a difference in long-term outcomes between radioiodine-treated and surgically treated patients, especially in terms of cardiovascular disease, and in particular among men, has thus not been described previously. This is possibly due to that fact that it has hardly been studied. There is general consensus that hyperthyroidism as such is associated with increased all-cause and cardiovascular mortality, something that has also been shown in another study by the present research group 19, 27 . Given the lack of randomized trials, it is thus difficult to separate any inherent effects of the disease from the side-effects of its treatment. There are no previous pathophysiological studies to suggest a direct harmful effect from radioiodine on the cardiovascular system. However, a recent study from Denmark 28 described an increased risk of cerebrovascular disease in both hyperthyroid patients and those with non-toxic goitre who were treated with radioiodine, a finding that might imply some detrimental effect from radioiodine per se. Furthermore, a meta-analysis 27 of patients treated for hyperthyroidism found all-cause mortality to be 17 per cent higher in radioiodine-treated patients than in others, but this finding did not reach statistical significance. Although these findings might not explain the sex difference found in the present study, radioiodine could represent a cardiovascular risk factor that would have a greater impact in a male population considering the higher cardiovascular risk profile among men in general. Another explanation for the present results might be found from a British study 29 , which showed that patients rendered hypothyroid by radioiodine treatment had lower mortality than those who became only euthyroid. Previous research 30 has suggested that men are less likely than women to become hypothyroid from treatment with radioiodine. Unfortunately, the database used in the present study did not contain reliable information regarding the thyroid status of study patients after treatment.
Strengths of this study include the fact that the cohort is likely to contain virtually all hyperthyroid individuals who received either radioiodine treatment or surgery in Stockholm during a defined time period. The mean duration of follow-up was long. The Swedish system of personal identity numbers, which allows for linkage between census data, local hospital registers and national registers, means that individuals are rarely lost to follow-up. By using different statistical methods, it was found that the overall results remained consistent across the analyses.
The most important weakness of this study was the fact that analyses of treatment outcomes were based solely on register data, which introduces a possibility of residual confounding that can be fully avoided only through prospective randomization. This was especially true with regard to the large difference in mean age between the treatment groups, which became evident in the sensitivity analysis where the introduction of an upper-age cut-off value resulted in a small loss of surgical patients but a large loss of radioiodine-treated patients. Although this change did not alter the results in general, the propensity score matching found an increased incidence of cancer deaths among surgically treated patients. However, as the number of events was small in that group, this could be interpreted as a chance finding. Another weakness pertains to the way in which the study patients were identified; by relying on one register for radioiodine treatments and another for surgery, it is thus possible that information on baseline co-morbidity was skewed. In addition, information was missing on patients treated with antithyroid drugs, as they were not part of this cohort. Furthermore, longitudinal data on each patient's thyroid status after treatment could not be obtained. Regarding the cause-specific mortality outcomes, it should be noted that the Swedish Causes of Death Register is less valid for some diagnoses than for others; malignant neoplasms and ischaemic heart disease are correctly classified in general, whereas validity is lower for other types of cardiovascular disease 20 . However, in the present cohort, ischaemic heart disease represented almost half of all cardiovascular causes of death.
Based on the present findings, it might be warranted to pay more attention to the possible long-term benefits of surgery as treatment for hyperthyroidism, especially among men. Current guidelines on the management of thyroid disease tend to focus on the short-term pros and cons of the options available, leaving much room for individual patient and physician preference. This fact, together with the existing regional differences worldwide, seems to indicate a measure of arbitrariness. Further research, in the form of RCTs, or observational studies on other cohorts, will ultimately be necessary to determine whether all treatment modalities are in fact equally safe, regardless of sex.
